GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomic Health Inc (FRA:G7H) » Definitions » Net Margin %

Genomic Health (FRA:G7H) Net Margin % : 16.35% (As of Sep. 2019)


View and export this data going back to . Start your Free Trial

What is Genomic Health Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Genomic Health's Net Income for the three months ended in Sep. 2019 was €17.0 Mil. Genomic Health's Revenue for the three months ended in Sep. 2019 was €103.8 Mil. Therefore, Genomic Health's net margin for the quarter that ended in Sep. 2019 was 16.35%.

The historical rank and industry rank for Genomic Health's Net Margin % or its related term are showing as below:


FRA:G7H's Net Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -11.145
* Ranked among companies with meaningful Net Margin % only.

Genomic Health Net Margin % Historical Data

The historical data trend for Genomic Health's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Health Net Margin % Chart

Genomic Health Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.92 -11.59 -4.25 -1.13 6.52

Genomic Health Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.07 8.52 11.95 14.01 16.35

Competitive Comparison of Genomic Health's Net Margin %

For the Diagnostics & Research subindustry, Genomic Health's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomic Health's Net Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genomic Health's Net Margin % distribution charts can be found below:

* The bar in red indicates where Genomic Health's Net Margin % falls into.



Genomic Health Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Genomic Health's Net Margin for the fiscal year that ended in Dec. 2018 is calculated as

Net Margin=Net Income (A: Dec. 2018 )/Revenue (A: Dec. 2018 )
=22.57/346.424
=6.52 %

Genomic Health's Net Margin for the quarter that ended in Sep. 2019 is calculated as

Net Margin=Net Income (Q: Sep. 2019 )/Revenue (Q: Sep. 2019 )
=16.974/103.834
=16.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genomic Health  (FRA:G7H) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Genomic Health Net Margin % Related Terms

Thank you for viewing the detailed overview of Genomic Health's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomic Health (FRA:G7H) Business Description

Traded in Other Exchanges
N/A
Address
301 Penobscot Drive, Redwood City, CA, USA, 94063
Genomic Health Inc provides genomic-based diagnostic tests that focus on the treatment of early-stage cancer. The firm's Oncotype DX tests analyze the expression levels of genes in tumor tissue samples and provide a numeric score that physicians can use to determine the aggressiveness of breast, colon, or prostate cancer. These test results can guide decisions about the use of chemotherapy, radiation, surgery, or other aggressive treatments. The Oncotype DX breast cancer test generates the majority of the firm's revenue, analyzing 21 genes to determine the optimal treatment for stage I, II, or IIa breast cancer. The majority of Genomic Health's sales occur within the United States.

Genomic Health (FRA:G7H) Headlines

No Headlines